Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""olanzapine"" wg kryterium: Temat


Tytuł :
Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats.
Autorzy :
Luo C; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.; School of Life Sciences, Central South University, Changsha, 410078, Hunan, China.
Wang X; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.
Huang HX; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.
Mao XY; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.
Zhou HH; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.
Liu ZQ; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. .; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China. .
Pokaż więcej
Źródło :
Psychopharmacology [Psychopharmacology (Berl)] 2021 Jan; Vol. 238 (1), pp. 239-248. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Journal Article
MeSH Terms :
Adjuvants, Pharmaceutic/*pharmacology
Gastrointestinal Microbiome/*drug effects
Liver/*drug effects
Metabolic Diseases/*prevention & control
Metformin/*pharmacology
Olanzapine/*adverse effects
Adjuvants, Pharmaceutic/administration & dosage ; Animals ; Bacteroides/isolation & purification ; Blood Glucose/metabolism ; Body Weight/drug effects ; Dose-Response Relationship, Drug ; Feces/microbiology ; Humans ; Lactobacillus gasseri/isolation & purification ; Liver/metabolism ; Male ; Metabolic Diseases/chemically induced ; Metformin/administration & dosage ; Olanzapine/administration & dosage ; RNA, Ribosomal, 16S/genetics ; Rats
SCR Organism :
Bacteroides acidifaciens
Czasopismo naukowe
Tytuł :
Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.
Autorzy :
Jena M; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Mishra A; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Mishra BR; Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Nath S; Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Maiti R; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India. .
Pokaż więcej
Źródło :
Psychopharmacology [Psychopharmacology (Berl)] 2020 Nov; Vol. 237 (11), pp. 3471-3480. Date of Electronic Publication: 2020 Aug 01.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antipsychotic Agents/*therapeutic use
Cardiovascular Diseases/*blood
Lurasidone Hydrochloride/*therapeutic use
Metabolic Diseases/*blood
Olanzapine/*therapeutic use
Schizophrenia/*blood
Adult ; Antipsychotic Agents/adverse effects ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/epidemiology ; Female ; Follow-Up Studies ; Humans ; Lipids/blood ; Lurasidone Hydrochloride/adverse effects ; Male ; Metabolic Diseases/chemically induced ; Metabolic Diseases/epidemiology ; Middle Aged ; Olanzapine/adverse effects ; Schizophrenia/drug therapy ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Autorzy :
Ithimakin S; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand. .
Theeratrakul P; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Laocharoenkiat A; Pharmacy Department, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Nimmannit A; Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Akewanlop C; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Soparattanapaisarn N; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Techawattanawanna S; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Korphaisarn K; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Danchaivijitr P; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Nov; Vol. 28 (11), pp. 5335-5342. Date of Electronic Publication: 2020 Mar 04.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Aprepitant/*therapeutic use
Dexamethasone/*administration & dosage
Nausea/*prevention & control
Olanzapine/*administration & dosage
Ondansetron/*administration & dosage
Vomiting/*prevention & control
Adult ; Aged ; Antiemetics/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemoprevention/methods ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dexamethasone/adverse effects ; Dose-Response Relationship, Drug ; Double-Blind Method ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Drug Therapy, Combination ; Emetics/administration & dosage ; Emetics/adverse effects ; Female ; Humans ; Induction Chemotherapy/adverse effects ; Male ; Middle Aged ; Nausea/chemically induced ; Neoplasms/drug therapy ; Neoplasms/pathology ; Olanzapine/adverse effects ; Ondansetron/adverse effects ; Placebos ; Quality of Life ; Treatment Outcome ; Vomiting/chemically induced ; Young Adult
SCR Protocol :
AC protocol
Czasopismo naukowe
Tytuł :
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Autorzy :
Johnsen E; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway; The Norwegian Centre for Mental Disorders Research Centre of Excellence, Bergen, Norway. Electronic address: .
Kroken RA; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway; The Norwegian Centre for Mental Disorders Research Centre of Excellence, Bergen, Norway.
Løberg EM; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway; The Norwegian Centre for Mental Disorders Research Centre of Excellence, Bergen, Norway.
Rettenbacher M; Medizinische Universität Innsbruck, Innsbruck, Austria.
Joa I; Stavanger University Hospital, Stavanger, Norway.
Larsen TK; Stavanger University Hospital, Stavanger, Norway; University of Bergen, Bergen, Norway.
Reitan SK; St Olav's University Hospital, Trondheim, Norway; Norges teknisk-naturvitenskapelige universitet, Trondheim, Norway.
Walla B; St Olav's University Hospital, Trondheim, Norway.
Alisauskiene R; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway.
Anda LG; Stavanger University Hospital, Stavanger, Norway.
Bartz-Johannessen C; Haukeland University Hospital, Bergen, Norway.
Berle JØ; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway; The Norwegian Centre for Mental Disorders Research Centre of Excellence, Bergen, Norway.
Bjarke J; Haukeland University Hospital, Bergen, Norway.
Fathian F; Norske Kvinners Sanitetsforening Olaviken Gerontopsychiatric Hospital, Erdal, Norway; The Norwegian Centre for Mental Disorders Research Centre of Excellence, Bergen, Norway.
Hugdahl K; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway.
Kjelby E; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway; The Norwegian Centre for Mental Disorders Research Centre of Excellence, Bergen, Norway.
Sinkeviciute I; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway; The Norwegian Centre for Mental Disorders Research Centre of Excellence, Bergen, Norway.
Skrede S; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway.
Stabell L; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway; The Norwegian Centre for Mental Disorders Research Centre of Excellence, Bergen, Norway.
Steen VM; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway; The Norwegian Centre for Mental Disorders Research Centre of Excellence, Bergen, Norway.
Fleischhacker WW; Medizinische Universität Innsbruck, Innsbruck, Austria.
Pokaż więcej
Źródło :
The lancet. Psychiatry [Lancet Psychiatry] 2020 Nov; Vol. 7 (11), pp. 945-954.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Pragmatic Clinical Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Amisulpride/*therapeutic use
Antipsychotic Agents/*therapeutic use
Aripiprazole/*therapeutic use
Olanzapine/*therapeutic use
Psychotic Disorders/*drug therapy
Schizophrenia/*drug therapy
Adolescent ; Adult ; Aged ; Amisulpride/adverse effects ; Antipsychotic Agents/adverse effects ; Aripiprazole/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Norway ; Olanzapine/adverse effects ; Psychiatric Status Rating Scales ; Treatment Outcome ; Weight Gain/drug effects ; Young Adult
Czasopismo naukowe
Tytuł :
Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis.
Autorzy :
Li R; Department of Stomatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhang Y; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhu W; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ding C; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Dai W; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, Hunan, China.
Su X; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Dai W; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiao J; Department of Mental Health, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xing Z; Department of Emergency Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Huang X; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 12; Vol. 10 (1), pp. 17028. Date of Electronic Publication: 2020 Oct 12.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Antipsychotic Agents/*therapeutic use
Lipid Metabolism/*drug effects
Lipids/*blood
Olanzapine/*therapeutic use
Schizophrenia/*drug therapy
Antipsychotic Agents/pharmacology ; Humans ; Olanzapine/pharmacology ; Schizophrenia/blood
Czasopismo naukowe
Tytuł :
The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults.
Autorzy :
Shrewsbury SB; Stephen B. Shrewsbury, Impel NeuroPharma, Inc, 201 Elliott Ave West, Ste 260, Seattle, WA 98119. .; Impel NeuroPharma, Inc, Seattle, Washington, USA.
Hocevar-Trnka J; Impel NeuroPharma, Inc, Seattle, Washington, USA.
Satterly KH; Impel NeuroPharma, Inc, Seattle, Washington, USA.
Craig KL; Impel NeuroPharma, Inc, Seattle, Washington, USA.
Lickliter JD; Nucleus Network, Melbourne, Australia.
Hoekman J; Impel NeuroPharma, Inc, Seattle, Washington, USA.
Pokaż więcej
Źródło :
The Journal of clinical psychiatry [J Clin Psychiatry] 2020 Jun 30; Vol. 81 (4). Date of Electronic Publication: 2020 Jun 30.
Typ publikacji :
Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Olanzapine/*adverse effects
Olanzapine/*pharmacokinetics
Administration, Intranasal ; Administration, Oral ; Adolescent ; Adult ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/adverse effects ; Antipsychotic Agents/pharmacokinetics ; Antipsychotic Agents/pharmacology ; Attention/drug effects ; Cross-Over Studies ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Healthy Volunteers ; Humans ; Hypnotics and Sedatives/pharmacology ; Injections, Intramuscular ; Male ; Middle Aged ; Neuropsychological Tests ; Olanzapine/administration & dosage ; Olanzapine/pharmacology ; Young Adult
Czasopismo naukowe
Tytuł :
Surface modified niosomes of olanzapine for brain targeting via nasal route; preparation, optimization, and in vivo evaluation.
Autorzy :
Khallaf RA; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Aboud HM; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Sayed OM; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Pokaż więcej
Źródło :
Journal of liposome research [J Liposome Res] 2020 Jun; Vol. 30 (2), pp. 163-173. Date of Electronic Publication: 2019 May 22.
Typ publikacji :
Journal Article
MeSH Terms :
Antipsychotic Agents/*pharmacology
Brain/*metabolism
Olanzapine/*pharmacology
Administration, Intranasal ; Animals ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/chemistry ; Brain/pathology ; Dose-Response Relationship, Drug ; Drug Carriers/administration & dosage ; Drug Carriers/chemical synthesis ; Drug Carriers/chemistry ; Drug Delivery Systems ; Liposomes/administration & dosage ; Liposomes/chemical synthesis ; Liposomes/chemistry ; Male ; Molecular Structure ; Olanzapine/administration & dosage ; Olanzapine/chemistry ; Particle Size ; Rats ; Structure-Activity Relationship ; Surface Properties ; Viscosity
Czasopismo naukowe
Tytuł :
Dual Fluorescence-colorimetric Silver Nanoparticles Based Sensor for Determination of Olanzapine: Analysis in Rat Plasma and Pharmaceuticals.
Autorzy :
Chavada VD; Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India.
Bhatt NM; Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India.
Sanyal M; Department of Chemistry, St. Xavier's College, Navrangpura, Ahmedabad, 380009, Gujarat, India.
Shrivastav PS; Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India. .
Pokaż więcej
Źródło :
Journal of fluorescence [J Fluoresc] 2020 Jul; Vol. 30 (4), pp. 955-967. Date of Electronic Publication: 2020 Jun 16.
Typ publikacji :
Journal Article
MeSH Terms :
Colorimetry*
Fluorescence*
Metal Nanoparticles/*chemistry
Olanzapine/*analysis
Silver/*chemistry
Animals ; Drug Compounding ; Male ; Olanzapine/pharmacokinetics ; Particle Size ; Rats ; Rats, Wistar ; Surface Properties
Czasopismo naukowe
Tytuł :
Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).
Autorzy :
Altschuler EL; Department of Physical Medicine and Rehabilitation, Metropolitan Hospital, New York, NY, USA. Electronic address: .
Kast RE; IIAIGC Study Center, 22 Church Street, Burlington, VT 05401, USA.
Pokaż więcej
Źródło :
Medical hypotheses [Med Hypotheses] 2020 Aug; Vol. 141, pp. 109774. Date of Electronic Publication: 2020 Apr 23.
Typ publikacji :
Letter
MeSH Terms :
Betacoronavirus*
Colchicine/*therapeutic use
Coronavirus Infections/*complications
Dapsone/*therapeutic use
Olanzapine/*therapeutic use
Pneumonia, Viral/*complications
Respiratory Distress Syndrome/*drug therapy
Adult ; COVID-19 ; Chemotaxis, Leukocyte/drug effects ; Colchicine/administration & dosage ; Dapsone/administration & dosage ; Humans ; Interleukin-8/physiology ; Neutrophils/drug effects ; Olanzapine/administration & dosage ; Pandemics ; Respiratory Distress Syndrome/etiology ; SARS-CoV-2
Opinia redakcyjna
Tytuł :
Adjunct Aripiprazole for Obsessive-Compulsive Symptoms Associated With Second-Generation Antipsychotics in 2 Patients With Schizophrenia: Anti-obsessional Efficacy of Partial Agonism.
Autorzy :
Yesilkaya UH; Department of Psychiatry Bakirkoy ProfMazhar Osman Training and Research Hospital for Psychiatry Neurology and Neurosurgery Istanbul, Turkey .
Balcioglu YH
Pokaż więcej
Źródło :
Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2020 Jul/Aug; Vol. 40 (4), pp. 412-414.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Aripiprazole/*therapeutic use
Obsessive-Compulsive Disorder/*drug therapy
Olanzapine/*adverse effects
Adult ; Antipsychotic Agents/adverse effects ; Antipsychotic Agents/therapeutic use ; Clozapine/therapeutic use ; Drug Therapy, Combination/methods ; Humans ; Male ; Obsessive-Compulsive Disorder/chemically induced ; Obsessive-Compulsive Disorder/complications ; Olanzapine/therapeutic use ; Schizophrenia/complications ; Schizophrenia/drug therapy ; Young Adult
Raport
Tytuł :
Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia.
Autorzy :
Nikolac Perkovic M; Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000, Zagreb, Croatia.
Sagud M; University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.; School of Medicine, University of Zagreb, Salata 3, 10000, Zagreb, Croatia.
Zivkovic M; University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
Uzun S; Department of General Psychiatry, University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10000, Zagreb, Croatia.; Faculty of Medicine, Josip Juraj Strossmayer University, Josipa Huttlera 4, 31000, Osijek, Croatia.
Nedic Erjavec G; Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000, Zagreb, Croatia.
Kozumplik O; Department of General Psychiatry, University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10000, Zagreb, Croatia.; Faculty of Medicine, Josip Juraj Strossmayer University, Josipa Huttlera 4, 31000, Osijek, Croatia.
Svob Strac D; Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000, Zagreb, Croatia.
Mimica N; School of Medicine, University of Zagreb, Salata 3, 10000, Zagreb, Croatia.; Department of General Psychiatry, University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10000, Zagreb, Croatia.
Mihaljevic Peles A; University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.; School of Medicine, University of Zagreb, Salata 3, 10000, Zagreb, Croatia.
Pivac N; Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000, Zagreb, Croatia. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Jun 22; Vol. 10 (1), pp. 10049. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Polymorphism, Single Nucleotide*
Antipsychotic Agents/*administration & dosage
Catechol O-Methyltransferase/*genetics
Olanzapine/*administration & dosage
Schizophrenia/*drug therapy
Adult ; Aged ; Antipsychotic Agents/therapeutic use ; Female ; Haplotypes ; Humans ; Male ; Middle Aged ; Olanzapine/therapeutic use ; Pharmacogenomic Variants ; Schizophrenia/genetics ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China.
Autorzy :
Yi ZM; Department of Pharmacy, Peking University Third Hospital , Beijing, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University , Beijing, China.; Institute for Drug Evaluation, Peking University Health Science Center , Beijing, China.
Men P; Department of Pharmacy, Peking University Third Hospital , Beijing, China.; Institute for Drug Evaluation, Peking University Health Science Center , Beijing, China.
Qu S; Real-World Insights, IQVIA , Shanghai, China.
Li C; Health Economics & Outcome Research, Sanofi , Shanghai, China.
Yu X; Department of Psychiatry, Peking University Sixth Hospital , Beijing, China.
Zhai S; Department of Pharmacy, Peking University Third Hospital , Beijing, China.; Institute for Drug Evaluation, Peking University Health Science Center , Beijing, China.
Pokaż więcej
Źródło :
Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2020 Jun; Vol. 20 (3), pp. 313-320. Date of Electronic Publication: 2020 Apr 26.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Amisulpride/*administration & dosage
Antipsychotic Agents/*administration & dosage
Olanzapine/*administration & dosage
Schizophrenia/*drug therapy
Amisulpride/economics ; Antipsychotic Agents/economics ; China ; Cost-Benefit Analysis ; Decision Support Techniques ; Humans ; Markov Chains ; Olanzapine/economics ; Quality-Adjusted Life Years ; Schizophrenia/economics ; Time Factors
Czasopismo naukowe
Tytuł :
Poloxamer-407-Co-Poly (2-Acrylamido-2-Methylpropane Sulfonic Acid) Cross-linked Nanogels for Solubility Enhancement of Olanzapine: Synthesis, Characterization, and Toxicity Evaluation.
Autorzy :
Khan KU; Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Bahawalpur, Punjab, 63100, Pakistan.
Akhtar N; Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Bahawalpur, Punjab, 63100, Pakistan.
Minhas MU; College of Pharmacy, University of Sargodha, University Road, Sargodha City, Punjab, Pakistan. .
Pokaż więcej
Źródło :
AAPS PharmSciTech [AAPS PharmSciTech] 2020 May 17; Vol. 21 (5), pp. 141. Date of Electronic Publication: 2020 May 17.
Typ publikacji :
Journal Article
MeSH Terms :
Cross-Linking Reagents*
Nanogels*
Antipsychotic Agents/*administration & dosage
Olanzapine/*administration & dosage
Poloxamer/*chemistry
Acrylamides ; Animals ; Antipsychotic Agents/chemistry ; Antipsychotic Agents/toxicity ; Biological Availability ; Drug Liberation ; Excipients ; Free Radicals ; Olanzapine/chemistry ; Olanzapine/toxicity ; Particle Size ; Rabbits ; Solubility
Czasopismo naukowe
Tytuł :
The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature.
Autorzy :
Saudemont G; Territorial Hub Pain Accompaniment Palliative care, Hospital center Antibes Juan-les-Pins, 107 avenue de Nice, F-06606, Antibes, France.
Prod'Homme C; University Lille, CNRS, CHU Lille, Palliative care unit, F-59000, Lille, France.; ETHICS (Experiment, Transhumanism, Human Interactions, Care and Society) - EA 7446, Lille Catholic University, Lille, France.
Da Silva A; Palliative care unit, Oscar Lambret center, 3 rue Frédéric Combemale, F-59020, Lille, France.
Villet S; Palliative care unit, Oscar Lambret center, 3 rue Frédéric Combemale, F-59020, Lille, France.
Reich M; Palliative care unit, Oscar Lambret center, 3 rue Frédéric Combemale, F-59020, Lille, France.
Penel N; Direction of Research and Innovation, Oscar Lambret center, 3 rue Frédéric Combemale, F-59020, Lille, France.; Lille University Hospital and Medical School, F-59045, Lille, France.
Gamblin V; Palliative care unit, Oscar Lambret center, 3 rue Frédéric Combemale, F-59020, Lille, France. .
Pokaż więcej
Źródło :
BMC palliative care [BMC Palliat Care] 2020 Apr 22; Vol. 19 (1), pp. 56. Date of Electronic Publication: 2020 Apr 22.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Antiemetics/*therapeutic use
Olanzapine/*standards
Palliative Medicine/*instrumentation
Antiemetics/standards ; Antipsychotic Agents/standards ; Antipsychotic Agents/therapeutic use ; Humans ; Nausea/drug therapy ; Nausea/prevention & control ; Olanzapine/therapeutic use ; Palliative Medicine/methods ; Palliative Medicine/trends ; Vomiting/drug therapy ; Vomiting/prevention & control
Czasopismo naukowe
Tytuł :
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Autorzy :
Iihara H; Department of Pharmacy, Gifu University Hospital, Gifu, Japan; Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan. Electronic address: .
Shimokawa M; Cancer Biostatistics Laboratory, National Hospital Organization Kyusyu Cancer Center, Fukuoka, Japan; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Hayasaki Y; Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Japan.
Fujita Y; Division of Pharmacy, Gunma Prefectural Cancer Center, Gunma, Japan.
Abe M; Division of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Takenaka M; Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Japan.
Yamamoto S; Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
Arai T; Division of Pharmacy, Gunma Prefectural Cancer Center, Gunma, Japan.
Sakurai M; Department of Pharmacy, Shizuoka Cancer Center, Shizuoka, Japan.
Mori M; Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Japan.
Nakamura K; Department of Gynecology, Gunma Prefectural Cancer Center, Gunma, Japan.
Kado N; Division of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Murase S; Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Japan.
Shimaoka R; Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Japan.
Suzuki A; Department of Pharmacy, Gifu University Hospital, Gifu, Japan; Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan.
Morishige KI; Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Japan.
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 Mar; Vol. 156 (3), pp. 629-635. Date of Electronic Publication: 2020 Jan 09.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antiemetics/*therapeutic use
Carboplatin/*adverse effects
Genital Neoplasms, Female/*drug therapy
Nausea/*prevention & control
Olanzapine/*therapeutic use
Vomiting/*prevention & control
Adult ; Aged ; Aprepitant/therapeutic use ; Carboplatin/administration & dosage ; Dexamethasone/therapeutic use ; Female ; Granisetron/therapeutic use ; Humans ; Middle Aged ; Nausea/chemically induced ; Olanzapine/adverse effects ; Vomiting/chemically induced
Czasopismo naukowe
Tytuł :
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
Autorzy :
Correll CU; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
Newcomer JW; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
Silverman B; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
DiPetrillo L; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
Graham C; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
Jiang Y; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
Du Y; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
Simmons A; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
Hopkinson C; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
McDonnell D; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
Kahn RS; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y. (Correll); Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Correll); Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin (Correll); Thriving Mind South Florida, Miami (Newcomer); Department of Psychiatry, Washington University School of Medicine, St. Louis (Newcomer); Alkermes, Inc., Waltham, Mass. (Silverman, DiPetrillo, Graham, Jiang, Du, Simmons, Hopkinson); Alkermes Pharma Ireland, Dublin (McDonnell); and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Kahn).
Pokaż więcej
Źródło :
The American journal of psychiatry [Am J Psychiatry] 2020 Dec 01; Vol. 177 (12), pp. 1168-1178. Date of Electronic Publication: 2020 Aug 14.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Naltrexone/*analogs & derivatives
Olanzapine/*adverse effects
Olanzapine/*therapeutic use
Schizophrenia/*drug therapy
Weight Gain/*drug effects
Adolescent ; Adult ; Antipsychotic Agents/adverse effects ; Antipsychotic Agents/therapeutic use ; Double-Blind Method ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Naltrexone/therapeutic use ; Narcotic Antagonists/therapeutic use ; Young Adult
Czasopismo naukowe
Tytuł :
The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats.
Autorzy :
Lian J; Antipsychotic Research Laboratory, Illawarra Health and Medical Research Institute, Wollongong, 2522, NSW, Australia; School of Medicine, and Molecular Horizons, University of Wollongong, Wollongong 2522, NSW, Australia.
Deng C; Antipsychotic Research Laboratory, Illawarra Health and Medical Research Institute, Wollongong, 2522, NSW, Australia; School of Medicine, and Molecular Horizons, University of Wollongong, Wollongong 2522, NSW, Australia. Electronic address: .
Pokaż więcej
Źródło :
Pharmacology, biochemistry, and behavior [Pharmacol Biochem Behav] 2020 Apr; Vol. 191, pp. 172878. Date of Electronic Publication: 2020 Feb 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Metabolic Syndrome/*chemically induced
Metabolic Syndrome/*prevention & control
Olanzapine/*adverse effects
Quinuclidines/*administration & dosage
Thiophenes/*administration & dosage
Adipose Tissue/drug effects ; Adiposity/drug effects ; Animals ; Behavior, Animal/drug effects ; Blood Glucose/drug effects ; Dose-Response Relationship, Drug ; Drug Interactions ; Eating/drug effects ; Female ; Locomotion/drug effects ; Metabolic Syndrome/blood ; Olanzapine/pharmacology ; Open Field Test ; Quinuclidines/pharmacology ; Rats ; Rats, Sprague-Dawley ; Receptor, Muscarinic M3/agonists ; Receptor, Muscarinic M3/antagonists & inhibitors ; Thiophenes/pharmacology ; Treatment Outcome ; Triglycerides/blood ; Weight Gain/drug effects
Czasopismo naukowe
Tytuł :
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
Autorzy :
Brunette MF; Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756. .; Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
Correll CU; Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, New York, USA.; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.
O'Malley SS; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.
McDonnell D; Alkermes Pharma Ireland Limited, Dublin, Ireland.
DiPetrillo L; Alkermes, Inc, Waltham, Massachusetts, USA.
Jiang Y; Alkermes, Inc, Waltham, Massachusetts, USA.
Simmons A; Alkermes, Inc, Waltham, Massachusetts, USA.
Silverman BL; Alkermes, Inc, Waltham, Massachusetts, USA.
Citrome L; New York Medical College, Valhalla, New York, USA.
Green AI; Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
Pokaż więcej
Źródło :
The Journal of clinical psychiatry [J Clin Psychiatry] 2020 Mar 10; Vol. 81 (2). Date of Electronic Publication: 2020 Mar 10.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Outcome Assessment, Health Care*
Alcoholism/*drug therapy
Antipsychotic Agents/*pharmacology
Naltrexone/*analogs & derivatives
Narcotic Antagonists/*pharmacology
Olanzapine/*pharmacology
Schizophrenia/*drug therapy
Adult ; Alcoholism/epidemiology ; Antipsychotic Agents/administration & dosage ; Comorbidity ; Female ; Humans ; Male ; Middle Aged ; Naltrexone/administration & dosage ; Naltrexone/pharmacology ; Narcotic Antagonists/administration & dosage ; Olanzapine/administration & dosage ; Schizophrenia/epidemiology
Czasopismo naukowe
Tytuł :
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
Autorzy :
Potkin SG; School of Medicine, University of California, Irvine, California, USA.
Kunovac J; Altea Research, Las Vegas, Nevada, USA.; Excell Research, Oceanside, California, USA.
Silverman BL; Alkermes, Inc, Waltham, Massachusetts, USA.
Simmons A; Alkermes, Inc, Waltham, Massachusetts, USA.
Jiang Y; Alkermes, Inc, Waltham, Massachusetts, USA.
DiPetrillo L; Alkermes, Inc, Waltham, Massachusetts, USA.
McDonnell D; Alkermes Pharma Ireland Limited, Connaught House, 1 Burlington Rd, Dublin D04 C5Y6, Ireland. .; Alkermes Pharma Ireland Limited, Dublin, Ireland.
Pokaż więcej
Źródło :
The Journal of clinical psychiatry [J Clin Psychiatry] 2020 Mar 03; Vol. 81 (2). Date of Electronic Publication: 2020 Mar 03.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Outcome Assessment, Health Care*
Symptom Flare Up*
Antipsychotic Agents/*pharmacology
Naltrexone/*analogs & derivatives
Narcotic Antagonists/*pharmacology
Olanzapine/*pharmacology
Schizophrenia/*drug therapy
Acute Disease ; Adult ; Antipsychotic Agents/administration & dosage ; Double-Blind Method ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Naltrexone/administration & dosage ; Naltrexone/pharmacology ; Narcotic Antagonists/administration & dosage ; Olanzapine/administration & dosage
Czasopismo naukowe
Tytuł :
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.
Autorzy :
Schmidt-Kraepelin C; Department of Psychiatry and Psychotherapy, Medical Faculty, LVR-Clinic Düsseldorf, Heinrich-Heine-University Duesseldorf, Bergische Landstraße 2, 40629, Duesseldorf, Germany. .
Feyerabend S; Department of Psychiatry and Psychotherapy, Medical Faculty, LVR-Clinic Düsseldorf, Heinrich-Heine-University Duesseldorf, Bergische Landstraße 2, 40629, Duesseldorf, Germany.
Engelke C; Department of Psychiatry and Psychotherapy, Medical Faculty, LVR-Clinic Düsseldorf, Heinrich-Heine-University Duesseldorf, Bergische Landstraße 2, 40629, Duesseldorf, Germany.
Riesbeck M; Department of Psychiatry and Psychotherapy, Medical Faculty, LVR-Clinic Düsseldorf, Heinrich-Heine-University Duesseldorf, Bergische Landstraße 2, 40629, Duesseldorf, Germany.
Meisenzahl-Lechner E; Department of Psychiatry and Psychotherapy, Medical Faculty, LVR-Clinic Düsseldorf, Heinrich-Heine-University Duesseldorf, Bergische Landstraße 2, 40629, Duesseldorf, Germany.
Gaebel W; Department of Psychiatry and Psychotherapy, Medical Faculty, LVR-Clinic Düsseldorf, Heinrich-Heine-University Duesseldorf, Bergische Landstraße 2, 40629, Duesseldorf, Germany.
Verde PE; Coordination Center for Clinical Trials, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Kolbe H; Coordination Center for Clinical Trials, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Correll CU; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.; Northwell Health, The Zucker Hillside Hospital, Psychiatry Research, Glen Oaks, NY, USA.; Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Leucht S; Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.
Heres S; Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.; kbo-Isar-Amper-Klinikum München-Ost, Munich, Germany.
Kluge M; Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Leipzig, Germany.
Makiol C; Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Leipzig, Germany.
Neff A; LVR-Klinikum Langenfeld, Langenfeld, Germany.
Lange C; LVR-Klinikum Langenfeld, Langenfeld, Germany.
Englisch S; Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.; Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany.
Zink M; Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.; Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany.
Langguth B; Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.
Poeppl T; Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.; Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany.
Reske D; LVR-Klinikum Köln, Cologne, Germany.
Gouzoulis-Mayfrank E; LVR-Klinikum Köln, Cologne, Germany.
Gründer G; Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.; Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany.
Hasan A; Department of Psychiatry and Psychotherapy, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany.
Brockhaus-Dumke A; Department of Psychiatry and Psychotherapy 1 und 2, Rheinhessen-Fachklinik Alzey, Academic Hospital of the University of Mainz, Alzey, Germany.
Jäger M; Department of Psychiatry II, Bezirkskrankenhaus Günzburg, Ulm University, Günzburg, Germany.
Baumgärtner J; Department of Psychiatry, Psychotherapy and Psychosomatics, Bezirkskrankenhaus Augsburg, University Augsburg, Augsburg, Germany.
Wobrock T; Department of Psychiatry and Psychotherapy, County Hospitals Darmstadt-Dieburg, Groß-Umstadt, Germany.; Department of Psychiatry and Psychotherapy, Georg-August-University Göttingen, Göttingen, Germany.
Cordes J; Department of Psychiatry and Psychotherapy, Medical Faculty, LVR-Clinic Düsseldorf, Heinrich-Heine-University Duesseldorf, Bergische Landstraße 2, 40629, Duesseldorf, Germany.; Department of Psychiatry and Psychotherapy, Kaiserswerther Diakonie, Florence Nightingale Hospital, Düsseldorf, Germany.
Pokaż więcej
Źródło :
European archives of psychiatry and clinical neuroscience [Eur Arch Psychiatry Clin Neurosci] 2020 Feb; Vol. 270 (1), pp. 83-94. Date of Electronic Publication: 2019 Sep 05.
Typ publikacji :
Clinical Trial Protocol; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Research Design*
Amisulpride/*pharmacology
Antipsychotic Agents/*pharmacology
Olanzapine/*pharmacology
Randomized Controlled Trials as Topic/*methods
Schizophrenia/*drug therapy
Acute Disease ; Adolescent ; Adult ; Aged ; Amisulpride/administration & dosage ; Amisulpride/adverse effects ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/adverse effects ; Double-Blind Method ; Drug Therapy, Combination ; Humans ; Middle Aged ; Multicenter Studies as Topic/methods ; Olanzapine/administration & dosage ; Olanzapine/adverse effects ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies